Small Miscellaneous
Market Cap
₹5,909 ₹5,909 Cr.
P/E
60.44
PEG
11.62
PEG = P/E ÷ 5yr Forward EPS CAGR
5yr Forward EPS CAGR Thesis - Base Case

- The thesis is validated by sustained demand across the Established Medicines and Transplant portfolios, continued distribution execution, and delivery against the FY27 revenue, margin, and customer-concentration watchpoints.- The bull path depends on stronger Transplant Maintenance growth and margin strength, while the bear path reflects portfolio weakness, pricing or concentration pressure, and EBITDA margin compression.

Key Ratios

Debt to Equity
Debt to Equity
-
Div Yield (%)
Div Yield (%)
-
Individual < 2 lac
Individual < 2 lac
19.32 %
Institutions
Institutions
1.51 %
Market cap
Market cap
5,909 Cr
No. of Shareholders
No. of Shareholders
36,502
OPM (%)
OPM (%)
27.46 %
PE
PE
60.44
Prom Holding
Prom Holding
70.68 %
ROCE (%)
ROCE (%)
8.85
ROE (%)
ROE (%)
12.85
Sales
Sales
370 Cr
  • Novartis India
  • Orchid Pharma
  • FDC
  • TJI Pharma - Small Cap
Last updated on 11 Sep 2026
  • Novartis India sells pain, cardio, transplant, CNS, wellness and gynae brands only in India. It uses contract makers and serves 150,000 doctors. ChrysCapital took control in July 2026 and holds 71% with new leadership.
  • Voveran at about ₹240Cr and Minipress XL at about ₹228Cr drive sales. Myfortic, Tegrital, Calcium-Sandoz and Methergin add smaller sales. Retina brands are pre-launch.
  • It ranks No.1 in its key therapy areas. It has six brands above ₹30Cr. Per management, legacy doctor loyalty makes in-house promotion the largest unlock.
  • It is building a 900-plus field force with a single distribution network. It is shifting from acute brands toward chronic therapies through M&A.
  • It held ₹668Cr net cash in March. The ₹1,250Cr Minipress deal uses cash plus debt with split not yet given.
  • Near-term profit depends on distribution cutover, field ramp and Minipress integration. Field costs run ahead of sales with one-time charges.
  • Tax appeals of about ₹305Cr plus DPCO claims of about ₹41Cr remain pending against about ₹817Cr net worth.
  • DRL cutover to owned sales 30 Sep 2026
    outsourced distribution ends and in-house sales begin. One-time costs fall in Q2-Q4FY27 with size still undisclosed.
  • Minipress XL closure and funding No timeline
    it adds ₹228Cr MAT sales for ₹1,250Cr, funded by cash plus debt. Funding mix is still undisclosed.
  • 900-plus field-force build No timeline
    it creates a 900-plus team and single distribution. Field costs run ahead of sales.
  • Income-tax appeals No timeline
    about ₹305Cr of appeals are pending. Outcome decides provision or cash outflow.
  • DPCO litigation No timeline
    about ₹41Cr of demands are pending. Outcome decides provision or cash outflow.
Price Range

See where the stock is trading versus its 52-week high and low.

Low
750
52W Range
High
2588
Timeline

Key company specific updates.

Custom financial statement

Edit rows

Forensics

9 Yes

Positive for this company

2 Neutral

Neutral for this company

6 No

Negative for this company

0 No Data

Insufficient data to analyse

Market Share

1.80 %
(as of Jul 22)
Anti - Diabetes - Market Share
0.06 %
(as of Jul 22)
Anti-Infectives - Market Share
0.09 %
(as of Nov 21)
Antineo Plastic - Market Share
0.14 %
(as of May 19)
Blood Related - Market Share
0.72 %
(as of Jul 22)
Cardiovascular - Market Share
0.03 %
(as of Nov 21)
Dermatology - Market Share

Revenue mix

Product Wise Break-Up

Location Wise Break-Up

Operational Metrics

    Select a Metric
    • Domestic Sales Growth - YoY (%)

    Peer Comparison

    Brands

    Voveran

    Corporate Actions

    Consolidated
    DATE
    DETAILS
    Show More
    Show Less
    Show More
    Show Less

    Suppliers

    • Navin Fluorine International Ltd.
    • Bharat Dynamics Ltd.
    • Neuland Laboratories Ltd.
    • Piramal Enterprises Ltd. - (Amalgamated)
    • Aarti Industries Ltd.

    FAQs on Novartis India Ltd. Business

    Novartis India Limited operates in pharmaceuticals, generics, over the counter (OTC), and animal health segments. It provides prescription medicines, retail generic products, and products for cattle and poultry markets.

    Novartis India major competitors are FDC, Guj. Themis Biosyn, Orchid Pharma, Sanofi India, Gufic Biosciences, Bliss GVS Pharma, Zota Health Care.
    Market Cap of Novartis India is ₹5,682 Crs.
    While the median market cap of its peers are ₹5,559 Crs.

    Novartis India seems to be financially stable compared to its competitors.
    The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.

    Company Filing

    2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010
    Annual Report FY26 FY25 FY24 FY23 FY22 FY21 FY20 FY19 FY18 FY17 FY16 FY15 FY14 FY13 FY12 FY11 FY10
    Earnings Release
    Investor Presentation Sep Dec
    Conference Call
    Conference Call SummaryCon Call Summary

    Discussions & Analysis

    Ideas Dashboard
    Results
    Timeline
    Watchlist
    Portfolio
    Alerts
    Stock Screener
    Market
    Raw Material